BRENTWOOD, Tenn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced that Eric Evans, Chief Executive Officer and Dave Doherty, Chief Financial Officer will meet with investors at the J.P. Morgan Healthcare Conference, including a presentation on Monday, January 8, 2024 at 5:15p.m. (Eastern Time).
Interested investors and other parties may listen to a simultaneous webcast of the event by logging onto the Investor Relations section of the company's website at www.surgerypartners.com. The replay will also be available on this same website for a limited time following the call.
To learn more about Surgery Partners, please visit the Company's website at www.surgerypartners.com. Surgery Partners uses its website as a channel of distribution for material Company information. Financial and other material information regarding Surgery Partners is routinely posted on the Company's website and is readily accessible.
About Surgery Partners
Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 180 locations in 32 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.
Contact:
Surgery Partners Investor Relations
(615) 234-8940
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$17.05 |
| Daily Change: | -0.01 -0.06 |
| Daily Volume: | 385,627 |
| Market Cap: | US$2.210B |
November 10, 2025 August 05, 2025 May 12, 2025 March 03, 2025 January 28, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load